Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 3/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283 | 0.85 | SLC6A3 (0.48) | SLC6A3SLC6A2SLC6A4MEN1ALDH1A1 | |
| SCHEMBL27258779 | 0.85 | CYP4F2 (0.58) | CYP4F2CYP4A11SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1069726 | 0.83 | FOLH1 (0.47) | CYP4F2CYP4A11MEN1ALDH1A1KMT2A | |
| SCHEMBL5863077 | 0.83 | CYP4F2 (0.53) | CYP4F2CYP4A11MEN1ALDH1A1KMT2A | |
| SCHEMBL18280416 | 0.81 | L3MBTL1 (0.48) | SLC6A3SLC6A2SLC6A4MEN1ALDH1A1 | |
| Bromomethane SCHEMBL7011845 | 0.80 | SLC6A3 (0.50) | SLC6A3SLC6A2SLC6A4MEN1ALDH1A1 | |
| SCHEMBL9531321 | 0.80 | BCAT2 (0.52) | SLC6A3SLC6A2SLC6A4MEN1ALDH1A1 | |
| SCHEMBL29389473 | 0.80 | BCAT2 (0.52) | SLC6A3SLC6A2SLC6A4MEN1ALDH1A1 | |
| SCHEMBL3459261 | 0.80 | CYP4F2 (0.36) | CYP4F2CYP4A11SLC6A3SLC6A4AKT1 | |
| SCHEMBL13989094 | 0.80 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | PPARG, CDK5, CDK5R1 | CYP4F2 3734/4885CYP4A11 1572/4885SLC6A3 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.